 ganciclovir recombinant human granulocyte-macrophage colony-stimulating factor treatment cytomegalovirus retinitis AIDS patients Ganciclovir effective progression cytomegalovirus CMV retinitis patients immune deficiency syndrome AIDS development neutropenia interruption ganciclovir therapy AIDS patients ongoing randomized trial AIDS patients CMV retinitis standard ganciclovir therapy ganciclovir recombinant human granulocyte-macrophage colony-stimulating factor rHuGM-CSF rHuGM-CSF subcutaneous injections doses neutrophil response individual patient Preliminary data evaluable patients ganciclovir ganciclovir rHuGM-CSF rHuGM-CSF administration trend decrease proportion patients absolute neutrophil count ANC cells/microliter overall incidence neutropenic episodes duration ganciclovir treatment interruption due development ANC cells/microliter days days rHuGM-CSF administration consistent proliferative effect agent human immunodeficiency virus infection Definitive conclusions coadministration rHuGM-CSF ganciclovir completion trial